Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of BioCentury, Week in Review: Clinical Results

BioCentury, Week in Review Current Issue
  • ArteFill: Phase III data

    Suneva Medical Inc., San Diego, Calif. Product: ArteFill Business: Dermatology Molecular target: Not available Description: Polymethylmethacrylate (PMMA) microspheres suspended in ultra-purified U.S. bovine collagen …

    Published on 5/20/2013
  • Fasiglifam: Phase III data

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Fasiglifam (TAK-875) Business: Endocrine/Metabolic Molecular target: Free fatty acid receptor 1 (FFAR1) (GPR40) Description: Free fatty acid receptor 1…

    Published on 5/20/2013
  • HTU-520: Phase II data

    Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530; Osaka:4530), Tosu, Japan Product: HTU-520 Business: Infectious Molecular target: NA Description: Terbinafine hydrochloride patch Indication: Treat onychomycosis Endpoint: …

    Published on 5/20/2013
  • Idelalisib: Phase II data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Idelalisib (formerly CAL-101, GS 1101, GS-1101) Business: Cancer Molecular target: Phosphoinositide 3-kinase (PI3K) delta Description: Small molecule …

    Published on 5/20/2013
  • Jetrea ocriplasmin: Phase IIa data

    ThromboGenics N.V. (Euronext:THR), Leuven, Belgium Product: Jetrea ocriplasmin (formerly Microplasmin) Business: Ophthalmic Molecular target: Not applicable Description: Recombinant microplasmin, a truncated form of the…

    Published on 5/20/2013
  • MPDL3280A: Phase I data

    Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: MPDL3280A, RG7446 Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (CD274 molecule) (PD-L1) (B7-H1…

    Published on 5/20/2013
  • MRX-6: Interim Phase II data

    Celsus Therapeutics plc (OTCQB:MRRBY), London, U.K. Product: MRX-6, MRX6 Business: Dermatology Molecular target: Phospholipase A2 (PLA2) Description: Topical multifunctional anti-inflammatory compound that inhibits …

    Published on 5/20/2013
  • N9-GP: Phase III data

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: N9-GP, pegylated recombinant human Factor IX (PEG-rFIX) Business: Hematology Molecular target: Factor IX Description: Glyco-pegylated derivative of …

    Published on 5/20/2013
  • NEPA: Phase III data

    Helsinn Healthcare S.A., Pazzallo-Lugano, Switzerland IS Pharma plc (LSE:ISPH), Chester, U.K. Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Product: NEPA (Netu-palo-FDC) Business: Gastrointestinal Molecular target: …

    Published on 5/20/2013
  • Nintedanib: Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Nintedanib (Vargatef) (BIBF 1120) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor; Platelet derived growth factor receptor (…

    Published on 5/20/2013
  • Niraparib: Phase I data

    Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Niraparib (formerly MK-4827) Business: Cancer Molecular target: Poly(ADP-ribose) polymerase (PARP) Description: …

    Published on 5/20/2013
  • Nivolumab: Interim Phase Ib data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Nivolumab (ONO-4538, MDX-1106, BMS-936558) Business: Cancer Molecular target: PD-1 receptor…

    Published on 5/20/2013
  • Obinutuzumab: Additional Phase III data

    Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Genentech Inc., South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Nippon Shinyaku Co. Ltd. (Tokyo:4516; Osaka:4516), Kyoto, Japan Roche (…

    Published on 5/20/2013
  • Oncotype DX prostate cancer assay: Additional data

    Genomic Health Inc. (NASDAQ:GHDX), Redwood City, Calif. Product: Oncotype DX prostate cancer assay Business: Diagnostic Molecular target: NA Description: Prostate biopsy test that measures the expression of 17 genes to …

    Published on 5/20/2013
  • PEGPH20: Phase Ib/II data

    Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif. Product: PEGPH20 (formerly PEGrHuPH20) Business: Cancer Molecular target: Hyaluronan Description: Recombinant human PH20 hyaluronidase enzyme conjugated to …

    Published on 5/20/2013
  • PX-866: Development discontinued

    Oncothyreon Inc. (NASDAQ:ONTY), Seattle, Wash. Product: PX-866 Business: Cancer Molecular target: Phosphoinositide 3-kinase (PI3K) Description: Oral phosphoinositide 3-kinase (PI3K) inhibitor Indication: Treat recurrent…

    Published on 5/20/2013
  • PX-866: Phase II data

    Oncothyreon Inc. (NASDAQ:ONTY), Seattle, Wash. Product: PX-866 Business: Cancer Molecular target: Phosphoinositide 3-kinase (PI3K) Description: Oral phosphoinositide 3-kinase (PI3K) inhibitor Indication: Treat recurrent…

    Published on 5/20/2013
  • Rotavac: Phase III data

    Bharat Biotech International Ltd., Hyderabad, India Product: Rotavac (ORV 116E) Business: Infectious Molecular target: NA Description: Live attenuated 116E rotavirus monovalent vaccine Indication: Prevent rotavirus …

    Published on 5/20/2013
  • SAR302503: Phase III data

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: SAR302503 (formerly TG101348) Business: Hematology Molecular target: Janus kinase-2 (JAK-2) Description: Selective oral Janus kinase-2 (JAK-2) inhibitor Indication…

    Published on 5/20/2013
  • Yervoy ipilimumab: Interim Phase Ib data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Yervoy ipilimumab (BMS-734016) Business: Cancer Molecular target: CTLA-4 (CD152) Description: Human mAb against CTLA-4 receptor Indication: Treat unresectable…

    Published on 5/20/2013
  • Cavatak: Final Phase I data

    Viralytics Ltd. (ASX:VLA), Pymble, Australia Product: Cavatak Business: Cancer Molecular target: Intercellular adhesion molecule-1 (ICAM-1) (CD54) Description: Coxsackievirus A21 (CVA21) Indication: Treat solid tumors …

    Published on 4/15/2013
  • Cevira: Final Phase IIb data

    Photocure ASA (OSE:PHO), Oslo, Norway Product: Cevira Business: Cancer Molecular target: NA Description: Photodynamic therapy (PDT) combining hexaminolevulinate (HAL) with illumination by a red light source Indication: …

    Published on 4/15/2013
  • Drisapersen: Phase IIb data

    Prosensa B.V., Leiden, the Netherlands GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Drisapersen (PRO051, GSK2402968) Business: Musculoskeletal Molecular target: NA Description: Antisense …

    Published on 4/15/2013
  • Hydroxychloroquine: Phase I data

    VG Life Sciences Inc. (Pink:VGLS), San Marino, Calif. Product: Hydroxychloroquine Business: Cancer Molecular target: NA Description: Hydroxychloroquine developed using Metabolic Disruption Technology (MDT) Indication: …

    Published on 4/15/2013
  • MVA-HCV: Final Phase II data

    Transgene S.A. (Euronext:TNG), Illkirch, France Product: MVA-HCV (TG4040) Business: Infectious Molecular target: Not applicable Description: Recombinant modified vaccinia Ankara (MVA) virus vector containing nucleotide …

    Published on 4/15/2013

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?